Onset of action of mometasone furoate nasal spray (NASONEX®) in seasonal allergic rhinitis

Authors:

Abstract
Background:Mometasone furoate nasal spray (MFNS, NASONEX®), is a new synthetic corticosteroid with considerable efficacy in the treatment of seasonal and perennial rhinitis and less than 0.1% systemic absorption. This study was designed to evaluate the time of onset of action of MFNS. The subjects were evaluated over the course of 2 weeks during the spring allergy season.Methods:The effects of MFNS 200 μg given once daily for 2 weeks were evaluated in a randomized, multicenter, double‐blind, placebo‐controlled study in 201 patients with seasonal allergic rhinitis. Clinically significant onset of action was assessed prospectively by special patient diary cards kept during the first 3 days of treatment.Results:By 12 h after initial dosage (the earliest evaluation), 28% of patients in the MFNS group experienced clinically significant relief, compared with 13% of those given placebo (P=0.01). Median time to at least moderate symptom relief in patients who received MFNS was 35.9 h, compared with more than 72 h in patients given placebo (PPPConclusions:MFNS provided rapid onset of clinically significant symptom relief in patients with seasonal allergic rhinitis.

This publication has 12 references indexed in Scilit: